ABLYNX Enters into a Research and Licence Agreemnt with WYETH
Ablynx, the pioneer in the discovery and development of Nanobodies, a novel class of antibody-derived therapeutic proteins,
Current Biology News
[CaRP] Can't open cache file.
[CaRP] Failed to open file: /home/ebiology/carp/autocache/7813cf194cde7f973d5c440156ed5047
[CaRP] Can't open remote newsfeed.
-
Archives
Categories
- Ablynx (1)
- Biotech Business News (120)
- Celera (1)
- Ranbaxy (2)
- Sigma-Aldrich (11)
Recent Entries
- BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance
- nexttec and Bio&Sell enter into sales and distribution agreement
- Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
- Bionas Signs Service Contract with Solvay Pharmaceuticals
- Progeniq joins Microsoft in Bio IT Alliance
- 3rd World Congress for Regenerative Medicine in Leipzig
- IMAGNA project team started work on therapeutic vaccination against cat fibrosarcoma
- Drug Therapy Management Accreditation - New First-Ever Standards Just Released by URAC
- MAF Currently Is Working to Cure Canine Cancer
- Pathway Diagnostics Announces Commercial Availability of SensiTrop HIV Co-receptor Tropism Assay
Copyright © BioWIRE : Latest Biotech & Pharma Industry News - Powered by WordPress
ProSense theme created by Dosh Dosh and The Wrong Advices.